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Abstract
Nodular pulmonary amyloidosis (NPA) is an
uncommon pathology of insoluble protein
depositing in pulmonary parenchyma. This
localized pulmonary form of amyloidosis is
most often found to contain combinations of
kappa and lambda immunoglobulin light chain
and immunoglobulin heavy chain proteins
with a polyclonal lymphoplasmacystic infil-
trate. Herein we present two cases of NPA of
the rarely reported monoclonal (light-chain
restricted) form with review of the literature
and discussion of the clinical, radiographic,
and histologic features of NPA.
Introduction
Amyloidosis is a disease that results from
tissue deposition of abnormally folded protein.
To date, more than 30 different types of amy-
loid have been described, which all share the
morphologic characteristics of fibrillar beta-
pleated sheet configuration.1 The most com-
mon type of amyloid is derived from
immunoglobulin light chain (AL) and usually
presents as a systemic disease, commonly
involving the kidneys, liver and spleen.2
Localized amyloid deposition can be organ spe-
cific where amyloid precursor is normally pro-
duced by the organ, or amyloid (most frequent-
ly AL amyloid) may deposit in a non-specific
localized form, confined to a specific organ
system.3 Amyloidosis involving the lung can be
divided broadly into cases associated with sys-
temic amyloidosis or those restricted to local-
ized pulmonary anatomy. 
Localized pulmonary forms are most often
found to contain of kappa or lambda AL.
Histologically, three main subtypes have been
described including tracheobronchial, diffuse
alveolar septal amyloidosis, and nodular pul-
monary (NPA).4 Of these types, NPA and tra-
cheobronchial are typically confined to the
lung with NPA being the most common form
accounting for about half of reported cases.
NPA is typically of the AL type and can be asso-
ciated with a polyclonal lymphoplasmacystic
infiltrate, though rare monoclonal types with
multiple lesions have been reported.5-10
Herein we report two clinical cases of mon-
oclonal nodular pulmonary amyloidosis includ-
ing one with a previously unreported presenta-
tion of a single, dominant lesion in addition to
a review of the literature.
Case Report
Case #1
A 55 year-old male with a chronic non-pro-
ductive cough and 20 pack-year smoking histo-
ry was referred to the surgical service with CT
finding of a 1.4 cm spiculated nodule in the
right middle lobe of his lung adjacent to the
visceral pleura. PET scan showed moderate
avidity with SUV of 4.2. CT-guided percuta-
neous lung biopsy revealed non-diagnostic
aspirate of rare atypical cells. Physical exam
revealed no neurologic dysfunction. Liver func-
tion tests and creatinine clearance were nor-
mal. Cardiac MRI demonstrated an interven-
tricular septum (IVS) of 8 mm, ejection frac-
tion (EF) of 75%, and normal left ventricular
(LV) mass for age and gender (56.2 g/m2).
There was also no evidence of late gadolinium
enhancement to suggest cardiac amyloid. 
Thoracoscopic wedge biopsy and mediasti-
nal lymph node dissection were obtained
which identified a 2.2 cm lesion consistent
with a localized pulmonary amyloidoma. The
wedge resection demonstrated a firm, homog-
enous dry grey-white mass puckering the pleu-
ra (2.2x1.5x1.0 cm). Histologically, the lesion
was a circumscribed nodule with acellular,
amorphous eosinophilic material filling the
alveolar spaces and foci of osteoid metaplasia.
Multinucleated giant cells and a mature
appearing lymphoplasmacytic infiltrate were
present, most notably at the edge of the lesion.
On Congo-Red stain, the material had a
salmon-colored appearance which showed
apple-green birefringence under polarized
light. Immunohistochemical stains revealed
lambda light chain restriction of the plasma
cells (Figure 1). The final diagnosis was pul-
monary amyloidoma with osteoid metaplasia.
Mediastinal lymph nodes showed no signifi-
cant histopathologic abnormality. 
Serum protein electrophoresis showed
hypoalbuminemia but was otherwise unre-
markable. Urine protein electrophoresis was
normal. Repeat serum protein electrophoresis
was essentially normal with no evidence of
monoclonal gammopathy. Serum free lambda
light chains were within normal limits. Free
kappa light chains were slightly elevated but
the kappa to lambda ratio was within the refer-
ence range. AA amyloid was negative by
immunostain. Abdominal fat pad aspirate was
performed to rule out systemic amyloidosis
with negative result. Of note, only Kappa and
Lambda antibodies are available in our labora-
tory. These immunostains were done to
demonstrate clonality of the surrounding plas-
macytic infiltrates. Because of the high back-
ground, use of these antibodies is limited to
characterize the nature of the amyloid.
Case #2
A 76 year-old male presented with severe
aortic valve stenosis with symptoms of dyspnea
on mild exertion and ostial LAD stenosis con-
firmed by cardiac catheterization. At this time,
he was known to have bilateral pulmonary nod-
ules in all lung lobes. By CT imaging, these
were suspicious for nodular pulmonary amyloi-
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dosis given their shape, pattern of calcifica-
tion, and stability in size. Echocardiogram
found preserved LVEF of 55% and no visualized
myocardial deposits. The IVS measured at 0.98
cm with no evidence of diastolic function.
Pulmonary function testing was normal, and
the patient had no history of smoking.
Repeat CT scan of the chest without con-
trast revealed multiple bilateral lung nodules
in all lung lobes with irregular calcifications
with associated septal thickening suggestive
of amyloid infiltration. Bilateral hilar and
mediastinal lymphadenopathy were slightly
increased in size from previous CT a year
prior, however, lung nodules were unchanged.
PET scan showed these lesions to have stan-
dardized uptake values ranging from 2.3-5.8
SUV. In addition, there was radiotracer uptake
in bilateral paratracheal, hilar, prevascular,
and subcarinal lymph nodes ranging from 3.6-
4.5 SUV. 
Transbronchial biopsies of bilateral hilar
lymph nodes as well as right upper and middle
lobe masses were non-diagnostic, thus left
upper lobe wedge resection was performed at
the time of aortic valve replacement and coro-
nary artery bypass grafting. Histology was con-
sistent with amyloidosis. The lung parenchy-
ma contained yellow brittle nodules with gross
central calcification. Light microscopy identi-
fied a deposit of eosinophilic homogenous
material with giant cell foreign body reaction
on hematoxylin and eosin stain. Congo Red
staining under polarized light revealed apple-
green birefringence confirming the presence
of amyloid. Immunohistochemistry showed
CD138+ plasma cell infiltration with
kappa/lambda light chain antibodies binding at
a kappa restricted ratio of 100:1, indicating a
monoclonal population. On serum protein elec-
trophoresis, the patient was found to have a
faint monoclonal band. Serum and urine free
light chains were minimal and within a normal
ratio. Bone marrow biopsy demonstrated an
atypical plasma cell infiltrate (8% plasma
cells), however it did not meet criteria for plas-
ma cell dyscrasia. Bone marrow biopsy also
showed no evidence of amyloid. These findings
granted the diagnosis of monoclonal gam-
mopathy of undetermined significance. 
Discussion
Amyloidosis can be particularly difficult to
diagnose because workup involves imaging,
blood, and urine studies – none of which alone
are diagnostic. Proper assessment of the amy-
loid involves typing the protein deposits by
immunohistochemical (IHC) staining,
immunogold electron microscopy, or mass
spectrometry.11 Typing of the amyloid is ideal
but is available only in highly specialized insti-
tutions. Congo red stain confirms the presence
of amyloid. Staining for lambda and kappa
light chains to assess clonality should be done,
but clonality is not necessarily associated with
systemic disease. Serum and urine protein
analysis is necessary to exclude an underlying
or concurrent amyloid producing plasma cell
dyscrasia or lymphoma. Plasma cell dyscrasia
work up includes serum protein electrophore-
sis, serum free light chain assays, serum and
urine immunofixation electrophoreses, and
bone marrow biopsy with flow cytometry. In
addition, of particular concern is the assess-
ment for systemic disease resulting in major
end organ damage (i.e. cardiac, liver, kidney,
or nervous system dysfunction.) Assessment of
cardiac function by echocardiography, scintig-
raphy, or magnetic resonance has become
standard as cardiac involvement is the major
determinant of long-term outcomes. While
amyloidosis is seen with some frequency in
clinical practice, NPA is less common.
Particularly of the popyclonal type, approxi-
mately one hundred cases have been reported
in the literature of NPA (Table 1).3,5-17 NPA is
typically of the AL variant, specifically lambda
light chain despite the usual association of AL
amyloid with systemic amyloidosis.2-4,15 The
amyloid is speculated to arise from a reaction
to chronic inflammatory conditions of the lung,
including connective tissue disorders, tubercu-
losis, or HIV infection. In keeping with this
presumptive origin, pulmonary amyloidoma is
thus usually associated with a polyclonal lym-
phoplasmacytic infiltrate at its periphery.15
Nine cases, including our two recent cases,
have been reported of otherwise histologically
typical pulmonary amyloidomas being associ-
ated with a monoclonal lymphoplasmacytic
infiltrate.18-23 Of these cases, age ranges from
55 to 73 with male predominance (7 of 9
cases). All cases demonstrated multifocal
lesions with the exception of our new case
presentation (Case 1). The relevant informa-
tion from these cases is listed in Table 2. Given
the rarity of this pathologic type, its signifi-
cance is not well understood.
Nodular pulmonary amyloidoma with associ-
ated monoclonal plasmacytic infiltrate, a local-
ized amyloid, is thus a rare entity. It is radi-
ographically and morphologically identical to
nodular pulmonary amyloidoma without light
                             Case Report
Table 1. Reported cases of pulmonary amyloidoma with associated polyclonal lympho-
plasmacytic reaction.
Reference       Average age (range)       Sex (M:F)         Size (cm)       Number of cases
Hui                                              64                                       NR                            1-4                                  28
Thompson                                NR                                      NR                           1-15                                 55
da Costa                             49 (28-59)                               3:3                            2-7                                   6
Pitz                                             48                                       1:0                            NR                                   1
Utz                                       67 (43-78)                               NR                            NR                                   7
Smith                                  79 (74-87)                               2:1                            .5-2                                   3
Cordier                                     NR                                      2:0                           1-3.5                                 2
Dacic                                  55 (25-65)                               3:3                            NR                                   6
Kawashima                               75                                       0:1                            NR                                   1
Podbielski                                 65                                       0:1                              2                                     1
Desai                                  59 (48-69)                               1:1                            NR                                   1
Pusztaszeri                               72                                       0:1                              5                                     1
Asad                                           72                                       0:1                            NR                                   1
NR, not reported.
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Figure 1. Immunohistochemistry for
kappa (A) and lambda (B) light chains
reveals lambda light change restriction of
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chain restriction, and may mimic many other
lesions on imaging and histology. A tissue
sample consisting of amorphous eosinophilic
material must be stained with Congo Red to
confirm the presence of amyloid. After making
the diagnosis of amyloidoma, the lesion should
be stained for kappa and lambda light chains to
determine clonality. Light chain restriction
may represent a low-grade lymphoproliferative
disorder, however associated significant sys-
temic disease has not been reported to date.
Further workup including serum and urine
protein electrophoresis is necessary to avoid
missing a diagnosis such as primary pul-
monary lymphoma or pulmonary light chain
disease which would require further treatment
and is associated with worse prognosis. 
The principle diagnostic concern with
regards to NPA in particular is exclusion of
underlying malignancy and systemic disease.
Much of this diagnostic goal is derived from
imaging properties of the NPA lesions.
Classical NPA can be identified by characteris-
tics including sharp lobulated contours, central
or irregular calcification, single or multiple
lesions of variable shapes and sizes with slow
growth over years.18 As with our case report,
nodules can be FDG-avid on PET scan, further
increasing the suspicion for malignancy. The
nodules may also display central calcification
further eliciting a potentially malignant pic-
ture. Both B cell lymphoma and mucosa-associ-
ated lymphoid tissue (MALT) must be ruled out
as both associations have been described in
rare cases.19-22 Diagnostic uncertainty and
symptoms secondary to mass effect often
prompt biopsy and surgical resection of these
lesions. Transbronchial or endobronchial biop-
sy can sometimes facilitate analysis, however
thoracoscopic wedge resection or open lung
biopsy are often needed for diagnosis certainty.
Conclusions
Nodular pulmonary amyloidoma with associ-
ated monoclonal plasmacytic infiltrate is a rare
entity. Proper radiographic, histologic, and IHC
workup can identify these lesions with partic-
ular attention to exclusion of systemic disease
and associated malignancy to identify those
patients who will benefit from directed treat-
ment strategies.
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Table 2. Reported cases of pulmonary amyloidoma with associated monoclonal light
chain lymphoplasmacytic reaction.
Reference           Age            Sex          Size (cm)      Number of lesions       Light chain
Original case              55                   M                        2.2                              Single                             Lambda
Original case              76                   M                    1.5-9.3                         Multiple                             Kappa
Miyamoto                     72                   M                    0.9-3.5                         Multiple                             Kappa
Ross                              60                    F                      0.7-2                          Multiple                               NR
Ross                              73                    F                        NR                            Multiple                               NR
Ihing                             67                   M                        2.5                            Multiple                           Lambda
Ihing                             66                   M                         3                              Multiple                           Lambda
Davis                             56                   M                        1.5                            Multiple                             Kappa
Murata                          63                   M                       NR                            Multiple                             Kappa
NR, not reported.
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